Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
Arianna Huffington's Thrive Global partners with Zepbound-maker Eli Lilly to share content on healthy habits where patients ...
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...
The Motley Fool29d
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly expects to have data from a late-stage trial involving orforglipron by April. This weight loss pill helped patients lose nearly 15% of their weight in a phase 2 trial. Lilly has been a ...
Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Yahoo Finance16d
Eli Lilly and Co (LLY) Is Among Billionaire Coleman’s Top Picks
In this article, we are going to take a look at where Eli Lilly and Co (NYSE ... His New York-based investment firm, Tiger Global Management, helped him carve his own path in the financial world ...
FiercePharma8d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
Medindia8d
Eli Lilly's Zepbound to Dominate Global Obesity Market
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...